Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: Focusing on the non‐overlap groups
Ibrahim Ayada, Laurens A. van Kleef, Louise J. M. Alferink, et al.
Liver International (2021) Vol. 42, Iss. 2, pp. 277-287
Closed Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming‐Hua Zheng, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S17-S31
Open Access | Times Cited: 223
Global multi-stakeholder endorsement of the MAFLD definition
Nahúm Méndez‐Sánchez, Elisabetta Bugianesi, Robert G. Gish, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 5, pp. 388-390
Open Access | Times Cited: 208
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
Mohammed Eslam, Hashem B. El‐Serag, Sven Francque, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 10, pp. 638-651
Closed Access | Times Cited: 161
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi‐Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 4, pp. 831-843
Open Access | Times Cited: 63
Natural history of metabolic dysfunction-associated steatotic liver disease
Vasileios Lekakis, George Papatheodoridis
European Journal of Internal Medicine (2023) Vol. 122, pp. 3-10
Closed Access | Times Cited: 54
The Rotterdam Study. Design update and major findings between 2020 and 2024
M. Arfan Ikram, Brenda C.T. Kieboom, Willem Pieter Brouwer, et al.
European Journal of Epidemiology (2024) Vol. 39, Iss. 2, pp. 183-206
Closed Access | Times Cited: 32
Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
Mohammad Habibullah, Khaleed Jemmieh, Amr Ouda, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 29
MAFLD identifies patients with significant hepatic fibrosis better than MASLD
Ziyan Pan, Said A. Al‐Busafi, Maheeba Abdulla, et al.
Hepatology International (2024) Vol. 18, Iss. 3, pp. 964-972
Closed Access | Times Cited: 15
Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study
Ibrahim Ayada, Laurens A. van Kleef, Huai Zhang, et al.
EBioMedicine (2022) Vol. 87, pp. 104392-104392
Open Access | Times Cited: 62
NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
Piero Portincasa
Internal and Emergency Medicine (2023) Vol. 18, Iss. 4, pp. 993-1006
Open Access | Times Cited: 25
MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 10, pp. 947-964
Open Access | Times Cited: 23
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Huai Zhang, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2024) Vol. 18, Iss. 4, pp. 1178-1201
Closed Access | Times Cited: 11
Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
João Paulo Margiotti dos Santos, Mariana Canevari de Maio, Monike Alves Lemes, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 1, pp. 498-498
Open Access | Times Cited: 37
MAFLD and CKD: An Updated Narrative Review
Alessandro Mantovani, Rosa Lombardi, Filippo Cattazzo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7007-7007
Open Access | Times Cited: 34
Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes
Alessandro Mantovani, Andrea Dalbeni, Giorgia Beatrice, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 4, pp. 968-968
Open Access | Times Cited: 28
Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
Ying Zhao, Yanni Zhou, Dan Wang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17514-17514
Open Access | Times Cited: 21
ACLY as a modulator of liver cell functions and its role in Metabolic Dysfunction-Associated Steatohepatitis
Paolo Convertini, Anna Santarsiero, Simona Todisco, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 17
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients
Maria Eva Argenziano, Mi Na Kim, Michele Montori, et al.
Hepatology International (2024) Vol. 18, Iss. S2, pp. 922-940
Closed Access | Times Cited: 7
Association between TyG index trajectory and new-onset lean NAFLD: a longitudinal study
Haoshuang Liu, Jingfeng Chen, Qian Qin, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 6
Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population
Young Lee, Eun Ju Cho, Eun Kyung Choe, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?
Diego García‐Compeán, Alan Rafael Jiménez-Rodríguez
Annals of Hepatology (2022) Vol. 27, Iss. 6, pp. 100765-100765
Open Access | Times Cited: 27
Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn’s disease but not Ulcerative Colitis: a prospective cohort study
Jie Chen, Lintao Dan, Xinru Tu, et al.
Hepatology International (2022) Vol. 17, Iss. 1, pp. 202-214
Open Access | Times Cited: 27
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
Eda Kaya, Yusuf Yılmaz
Therapeutic Advances in Endocrinology and Metabolism (2022) Vol. 13
Open Access | Times Cited: 25
The relationship between metabolic dysfunction‐associated fatty liver disease and low muscle mass in an asymptomatic Korean population
Ji Yeon Seo, Eun Ju Cho, Min Joo Kim, et al.
Journal of Cachexia Sarcopenia and Muscle (2022) Vol. 13, Iss. 6, pp. 2953-2960
Open Access | Times Cited: 23
Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: a population-based cross-sectional study
Qingdan Liu, MeiLan K. Han, Meilan Li, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top